| The Patient Cohort of the National Center for Precision Medicine in Leukemia (NCT05326919) | Assistance Publique - Hôpitaux de Paris | 2022-03-28 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS (NCT04358393) | Ascentage Pharma Group Inc. | 2020-12-04 |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (NCT04128748) | M.D. Anderson Cancer Center | 2020-05-27 |
| Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia (NCT04262843) | City of Hope Medical Center | 2020-02-07 |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT (NCT04217278) | University of Birmingham | 2020-01-27 |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04047641) | M.D. Anderson Cancer Center | 2019-10-22 |
| RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome (NCT04021368) | Ryvu Therapeutics SA | 2019-09-04 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies (NCT02530034) | M.D. Anderson Cancer Center | 2019-01-31 |
| Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes (NCT03824080) | GWT-TUD GmbH | 2018-12-20 |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (NCT03672539) | M.D. Anderson Cancer Center | 2018-11-07 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (NCT03630991) | M.D. Anderson Cancer Center | 2018-10-11 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers (NCT03589729) | M.D. Anderson Cancer Center | 2018-09-19 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT03358719) | Roswell Park Cancer Institute | 2018-03-27 |
| Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome (NCT03047993) | M.D. Anderson Cancer Center | 2017-11-15 |
| Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome (NCT03094637) | M.D. Anderson Cancer Center | 2017-11-06 |
| Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT03067571) | M.D. Anderson Cancer Center | 2017-10-27 |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies (NCT03263637) | AstraZeneca | 2017-10-24 |
| Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia (NCT03214562) | M.D. Anderson Cancer Center | 2017-09-26 |
| Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT02861417) | M.D. Anderson Cancer Center | 2016-08-05 |
| Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes (NCT02131597) | M.D. Anderson Cancer Center | 2014-11-10 |
| Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT02029950) | National Cancer Institute (NCI) | 2013-12-16 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies (NCT01823198) | M.D. Anderson Cancer Center | 2013-06-11 |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. (NCT01236144) | Cardiff University | 2011-04-01 |
| Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias (NCT01149915) | Threshold Pharmaceuticals | 2010-06-01 |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT00801489) | M.D. Anderson Cancer Center | 2007-04-04 |